002773SZSE

Announcement on Adjusting the Exercise Price of the 2022 Stock Appreciation Rights Incentive Plan

✨ AI Summary

This announcement details the adjustments to the exercise price of the company's 2022 stock appreciation rights incentive plan. Key decisions include the approval of the adjustment at various board meetings, with the new exercise price set between 11.64 and 12.94 CNY per share. The adjustments aim to align the incentive plan with the company's performance and shareholder interests.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Chengdu Kanghong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") announces the following regarding the adjustment of the exercise price of the 2022 stock appreciation rights incentive plan:

  1. Relevant Approval Procedures

On June 2, 2026, the Company held the 19th meeting of the 8th Board of Directors, which approved the adjustment regarding the exercise price of the 2022 stock appreciation rights incentive plan.

On June 30, 2022, the Company held the 15th meeting of the 7th Board of Directors, which approved the "2022 Stock Appreciation Rights Incentive Plan" and its key points. The Company independently expressed its views on the matter.

On June 30, 2022, the Company held the 12th meeting of the 7th Board of Supervisors, which approved the "2022 Stock Appreciation Rights Incentive Plan" and its key points.

On July 1 to July 10, 2022, the Company conducted a survey regarding the 2022 stock appreciation rights.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.